Article summary
Germany’s decision to permit psilocybin therapy for patients with treatment-resistant depression—under a compassionate use policy—marks a pivotal shift in European drug policy. It may set a precedent for others in the region exploring psychedelic-assisted treatments. Unlike centralized models that require regulatory approvals, Germany’s model empowers licensed psychiatrists to make case-by-case decisions on psilocybin treatment. They […] The post Psilocybin Enters German Psychiatry: A Clinical Milestone for Mental Health appeared first on Psychedelics Today.
Continue to the original publication for the complete article.